person · Reporting owner
STEELE GLENN JR MD PHD
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Director | September 30, 2026 | October 02, 2026 |
| WELLCARE HEALTH PLANS, INC.WCG · Entity 152183 | Director | May 23, 2018 | May 24, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,500 |
Ending reported balance
After 2026-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-30 · Exercise / conversion · Acquired 12,000 · Balance 34,500 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 9, 2026 Row 2 · 2026-09-30 · Sale · Disposed 12,000 · Balance 22,500 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 9, 2026 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.23 · Expires 2027-01-02 | Direct | 0 |
Reported balance
After 2026-09-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-30 · Exercise / conversion · Disposed 12,000 · Balance 0 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 9, 2026 F2: Currently exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 9, 2026
F2: Currently exercisable.
WELLCARE HEALTH PLANS, INC.
Report date May 23, 2018 · Filed May 24, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,139 |
Reported balance
After 2018-05-23 transaction · row 1
1 source rowRow 1 · 2018-05-23 · Exercise / conversion · Acquired 1,017 · Balance 5,139 F1: Vesting of restricted stock units granted to the Reporting Person on May 24, 2017. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-05-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-05-23 · Exercise / conversion · Disposed 1,017 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of WCG common stock. F3: The restricted stock units vested in full on May 23, 2018. Vested shares are delivered to the Reporting Person upon vest. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 847 |
Reported balance
After 2018-05-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-23 · Grant · Acquired 847 · Balance 847 F2: Each restricted stock unit represents a contingent right to receive one share of WCG common stock. F4: The restricted stock units vest in full on the earlier of May 23, 2019 and the date of the Registrant's next annual meeting of stockholders. Vested shares will be delivered to the Reporting Person upon vest. |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting of restricted stock units granted to the Reporting Person on May 24, 2017.
F2: Each restricted stock unit represents a contingent right to receive one share of WCG common stock.
F3: The restricted stock units vested in full on May 23, 2018. Vested shares are delivered to the Reporting Person upon vest.
F4: The restricted stock units vest in full on the earlier of May 23, 2019 and the date of the Registrant's next annual meeting of stockholders. Vested shares will be delivered to the Reporting Person upon vest.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CEPHEID
Report date November 04, 2016 · Filed November 07, 2016
Section 16 reporting ended · disclosed 2016-11-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-11-04 transaction · row 1
1 source rowRow 1 · 2016-11-04 · Disposition to issuer · Disposed 14,677 · Balance 0 F1: This number includes RSUs previously reported on Table I that at closing, were accelerated and converted into the right to receive $53 per share, without interest. F2: On September 2, 2016, the Issuer entered into an Agreement and Plan of Merger ("Merger Agreement") with Danaher Corporation, a Delaware corporation (the "Acquirer"), and Copper Merger Sub, Inc., a California corporation and a wholly-owned subsidiary of the Acquirer. Upon the closing of the transactions contemplated by the Merger Agreement on November 4, 2016 (the "Closing"), each of the Reporting Person's shares of the Issuer's Common Stock was cancelled and converted into the right to receive $53.00, without interest (the "Merger Consideration"). |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.85 · Expires 2018-04-26 | Direct | 0 |
Reported balance
After 2016-11-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-11-04 · Disposition to issuer · Disposed 18,750 · Balance 0 F3: Upon the Closing, 100% of these options were cancelled and converted into the right to receive an amount of cash equal to the number of shares outstanding under this option multiplied by $53 minus the option exercise price. F4: 1/3 of the shares subject to the grant vest and become exercisable on each anniversary of the grant date, subject to the continuing service of the Reporting Person on the vesting date. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.72 · Expires 2019-04-24 | Direct | 0 |
Reported balance
After 2016-11-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-11-04 · Disposition to issuer · Disposed 7,800 · Balance 0 F3: Upon the Closing, 100% of these options were cancelled and converted into the right to receive an amount of cash equal to the number of shares outstanding under this option multiplied by $53 minus the option exercise price. F5: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.13 · Expires 2020-04-30 | Direct | 0 |
Reported balance
After 2016-11-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-11-04 · Disposition to issuer · Disposed 7,800 · Balance 0 F3: Upon the Closing, 100% of these options were cancelled and converted into the right to receive an amount of cash equal to the number of shares outstanding under this option multiplied by $53 minus the option exercise price. F5: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.59 · Expires 2021-04-22 | Direct | 0 |
Reported balance
After 2016-11-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-11-04 · Disposition to issuer · Disposed 16,300 · Balance 0 F3: Upon the Closing, 100% of these options were cancelled and converted into the right to receive an amount of cash equal to the number of shares outstanding under this option multiplied by $53 minus the option exercise price. F5: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.70 · Expires 2022-04-28 | Direct | 0 |
Reported balance
After 2016-11-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2016-11-04 · Disposition to issuer · Disposed 16,300 · Balance 0 F6: Upon the Closing, this option was cancelled and ceased to exist without receiving any payment therefor. F5: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.59 · Expires 2023-04-26 | Direct | 0 |
Reported balance
After 2016-11-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2016-11-04 · Disposition to issuer · Disposed 16,300 · Balance 0 F7: Upon the Closing, 100% of this option's vesting was accelerated and converted into the right to receive an amount of cash equal to the number of shares outstanding under the option multiplied by $53.00 minus the exercise price. F5: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This number includes RSUs previously reported on Table I that at closing, were accelerated and converted into the right to receive $53 per share, without interest.
F2: On September 2, 2016, the Issuer entered into an Agreement and Plan of Merger ("Merger Agreement") with Danaher Corporation, a Delaware corporation (the "Acquirer"), and Copper Merger Sub, Inc., a California corporation and a wholly-owned subsidiary of the Acquirer. Upon the closing of the transactions contemplated by the Merger Agreement on November 4, 2016 (the "Closing"), each of the Reporting Person's shares of the Issuer's Common Stock was cancelled and converted into the right to receive $53.00, without interest (the "Merger Consideration").
F3: Upon the Closing, 100% of these options were cancelled and converted into the right to receive an amount of cash equal to the number of shares outstanding under this option multiplied by $53 minus the option exercise price.
F4: 1/3 of the shares subject to the grant vest and become exercisable on each anniversary of the grant date, subject to the continuing service of the Reporting Person on the vesting date.
F5: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date.
F6: Upon the Closing, this option was cancelled and ceased to exist without receiving any payment therefor.
F7: Upon the Closing, 100% of this option's vesting was accelerated and converted into the right to receive an amount of cash equal to the number of shares outstanding under the option multiplied by $53.00 minus the exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 2, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $11.23 | $0.00 |
DisclosureSEC source: 0001269131-26-000005 · form4-10022026_051001.xml · derivative · entry 3 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 9, 2026 F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 12,000 | $65.16 | $781,920.00 |
DisclosureSEC source: 0001269131-26-000005 · form4-10022026_051001.xml · nonDerivative · entry 2 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,500 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 9, 2026 Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 12,000 | $11.23 | $134,760.00 |
DisclosureSEC source: 0001269131-26-000005 · form4-10022026_051001.xml · nonDerivative · entry 1 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 9, 2026 Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 3,475 | $0.00 Strike: $76.74 | $0.00 |
DisclosureSEC source: 0001269131-26-000003 · form4-01062026_050101.xml · derivative · entry 5 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,475 Underlying: Common Stock · 3,475 shares Expires 2036-01-01 F4 · derivative.exercise_date: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $30.86 | $0.00 |
DisclosureSEC source: 0001269131-26-000003 · form4-01062026_050101.xml · derivative · entry 4 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 8, 2025. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001269131-26-000003 · form4-01062026_050101.xml · nonDerivative · entry 3 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,500 F2 · shares: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 12,000 | $76.35 | $916,200.00 |
DisclosureSEC source: 0001269131-26-000003 · form4-01062026_050101.xml · nonDerivative · entry 2 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,500 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 8, 2025. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 12,000 | $30.86 | $370,320.00 |
DisclosureSEC source: 0001269131-26-000003 · form4-01062026_050101.xml · nonDerivative · entry 1 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 8, 2025. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 8,800 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001415889-25-001028 · form4-01072025_050128.xml · derivative · entry 2 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,800 Underlying: Common Stock · 8,800 shares Expires 2035-01-02 F2 · derivative.exercise_date: This option was granted on January 3, 2025 and vests over one year in twelve equal monthly installments, commencing on February 3, 2025. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001028 · form4-01072025_050128.xml · nonDerivative · entry 1 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 F1 · shares: Restricted stock units granted on January 3, 2025 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 17, 2025 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 3, 2026. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001415889-24-004099 · form4-02162024_040203.xml · derivative · entry 2 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-02-14 F2 · derivative.exercise_date: This option was granted on February 15, 2024 and vests over one year in twelve equal monthly installments, commencing on March 15, 2024. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004099 · form4-02162024_040203.xml · nonDerivative · entry 1 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,500 F1 · shares: Restricted stock units granted on February 15, 2024 that vest over one year, with one-third (1/3) of the shares underlying the RSUs vesting on June 18, 2024 and the remaining two-thirds (2/3) of the original shares underlying the RSUs vesting on February 15, 2025. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (i) four years from the date of grant and (ii) the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:12 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001415889-23-000670 · form4-01092023_090113.xml · derivative · entry 2 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-01-04 F2 · derivative.exercise_date: This option was granted on January 5, 2023 and vests over one year in twelve equal monthly installments, commencing on February 5, 2023. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:12 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000670 · form4-01092023_090113.xml · nonDerivative · entry 1 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 F1 · shares: Restricted stock units granted on January 5, 2023 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 6, 2023 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 5, 2024. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (i) four years from the date of grant and (ii) the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 12,000 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001179110-22-000383 · edgar.xml · derivative · entry 2 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-01-06 F2 · derivative.exercise_date: This option was granted on January 7, 2022 and vests over one year in twelve equal monthly installments, commencing on February 7, 2022. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000383 · edgar.xml · nonDerivative · entry 1 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 F1 · shares: Restricted stock units granted on January 7, 2022 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 8, 2022 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 7, 2023. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (i) four years from the date of grant and (ii) the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:04 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 10,000 | $0.00 Strike: $66.49 | $0.00 |
DisclosureSEC source: 0001179110-21-000459 · edgar.xml · derivative · entry 2 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-05 F2 · derivative.exercise_date: This option was granted on January 6, 2021 and vests over one year in twelve equal monthly installments, commencing on February 6, 2021. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:04 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 1,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-000459 · edgar.xml · nonDerivative · entry 1 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300 F1 · shares: Restricted stock units ("RSUs") granted on January 6, 2021 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 8, 2021 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 6, 2022. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (i) four years from the date of grant and (ii) the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:38 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 10,000 | $0.00 Strike: $51.16 | $0.00 |
DisclosureSEC source: 0001070081-20-000044 · wf-form4_158050670295835.xml · derivative · entry 2 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-01-28 F2 · derivative.exercise_date: This option was granted on January 29, 2020 and vests over one year in twelve equal monthly installments, commencing on February 29, 2020. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:38 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 1,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001070081-20-000044 · wf-form4_158050670295835.xml · nonDerivative · entry 1 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 F1 · shares: Restricted stock units ("RSUs") granted on January 29, 2020 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 10, 2020 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 29, 2021. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (i) four years from the date of grant and (ii) the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 22:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001104659-19-003205 · a4.xml · derivative · entry 1 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2029-01-21 F1 · derivative.exercise_date: This option was granted on January 22, 2019 and vests over one year in twelve equal monthly installments, commencing on February 22, 2019. Read SEC document |
| May 23, 2018 Filed May 24, 2018 16:48 UTC | WELLCARE HEALTH PLANS, INC. WCG · Entity 152183 | GrantRestricted Stock Units · Derivative | 847 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-025536 · doc1.xml · derivative · entry 3 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847 Underlying: Common Stock · 847 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of WCG common stock. F4 · derivative.exercise_date: The restricted stock units vest in full on the earlier of May 23, 2019 and the date of the Registrant's next annual meeting of stockholders. Vested shares will be delivered to the Reporting Person upon vest. F4 · derivative.expiration_date: The restricted stock units vest in full on the earlier of May 23, 2019 and the date of the Registrant's next annual meeting of stockholders. Vested shares will be delivered to the Reporting Person upon vest. Read SEC document |
| May 23, 2018 Filed May 24, 2018 16:48 UTC | WELLCARE HEALTH PLANS, INC. WCG · Entity 152183 | Exercise / conversionRestricted Stock Units · Derivative | 1,017 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-025536 · doc1.xml · derivative · entry 2 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,017 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of WCG common stock. F3 · derivative.exercise_date: The restricted stock units vested in full on May 23, 2018. Vested shares are delivered to the Reporting Person upon vest. F3 · derivative.expiration_date: The restricted stock units vested in full on May 23, 2018. Vested shares are delivered to the Reporting Person upon vest. Read SEC document |
| May 23, 2018 Filed May 24, 2018 16:48 UTC | WELLCARE HEALTH PLANS, INC. WCG · Entity 152183 | Exercise / conversionCommon Stock | 1,017 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-025536 · doc1.xml · nonDerivative · entry 1 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of restricted stock units granted to the Reporting Person on May 24, 2017. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 21:17 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 14,000 | $0.00 Strike: $18.01 | $0.00 |
DisclosureSEC source: 0001070081-18-000025 · wf-form4_151518704257207.xml · derivative · entry 1 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2028-01-02 F1 · derivative.exercise_date: This option was granted on January 3, 2018 and vests over one year in twelve equal monthly installments, commencing on February 3, 2018. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 16:33 UTC | WELLCARE HEALTH PLANS, INC. WCG · Entity 152183 | SaleCommon Stock | 1,600 | $172.66 | $276,248.96 |
DisclosureSEC source: 0001140361-17-032034 · doc1.xml · nonDerivative · entry 2 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,122 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.49 to $172.95, inclusive. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 16:33 UTC | WELLCARE HEALTH PLANS, INC. WCG · Entity 152183 | SaleCommon Stock | 6,774 | $171.81 | $1,163,851.78 |
DisclosureSEC source: 0001140361-17-032034 · doc1.xml · nonDerivative · entry 1 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,722 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.41 to $172.29, inclusive. The reporting person undertakes to provide to WellCare Health Plans, Inc., any security holder of WellCare Health Plans, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| May 24, 2017 Filed May 25, 2017 18:03 UTC | WELLCARE HEALTH PLANS, INC. WCG · Entity 152183 | GrantRestricted Stock Units · Derivative | 1,017 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022412 · doc1.xml · derivative · entry 3 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,017 Underlying: Common Stock · 1,017 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of WCG common stock. F4 · derivative.exercise_date: The restricted stock units vest in full on the earlier of May 24, 2018 and the date of the Registrant's next annual meeting of stockholders. Shares will be delivered to the reporting person upon vest. F4 · derivative.expiration_date: The restricted stock units vest in full on the earlier of May 24, 2018 and the date of the Registrant's next annual meeting of stockholders. Shares will be delivered to the reporting person upon vest. Read SEC document |
| May 24, 2017 Filed May 25, 2017 18:03 UTC | WELLCARE HEALTH PLANS, INC. WCG · Entity 152183 | Exercise / conversionRestricted Stock Units · Derivative | 1,644 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022412 · doc1.xml · derivative · entry 2 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,644 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of WCG common stock. F3 · derivative.exercise_date: The restricted stock units vested in full on May 24, 2017. Vested shares are delivered to the Reporting Person upon vest. F3 · derivative.expiration_date: The restricted stock units vested in full on May 24, 2017. Vested shares are delivered to the Reporting Person upon vest. Read SEC document |
| May 24, 2017 Filed May 25, 2017 18:03 UTC | WELLCARE HEALTH PLANS, INC. WCG · Entity 152183 | Exercise / conversionCommon Stock | 1,644 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022412 · doc1.xml · nonDerivative · entry 1 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of restricted stock units granted to the Reporting Person on May 25, 2016. Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 00:23 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 12,000 | $0.00 Strike: $11.23 | $0.00 |
DisclosureSEC source: 0001070081-17-000035 · wf-form4_148366220139677.xml · derivative · entry 1 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-01-02 F1 · derivative.exercise_date: This option was granted on January 3, 2017 and vests over one year in twelve equal monthly installments, commencing on February 3, 2017. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 19:41 UTC | CEPHEID CPHD · Entity 181259 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 16,300 | $0.00 Strike: $36.59 | $0.00 |
DisclosureSEC source: 0001209191-16-148758 · doc4.xml · derivative · entry 7 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,300 shares Expires 2023-04-26 F7 · shares: Upon the Closing, 100% of this option's vesting was accelerated and converted into the right to receive an amount of cash equal to the number of shares outstanding under the option multiplied by $53.00 minus the exercise price. F5 · derivative.exercise_date: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 19:41 UTC | CEPHEID CPHD · Entity 181259 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 16,300 | $0.00 Strike: $56.70 | $0.00 |
DisclosureSEC source: 0001209191-16-148758 · doc4.xml · derivative · entry 6 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,300 shares Expires 2022-04-28 F6 · shares: Upon the Closing, this option was cancelled and ceased to exist without receiving any payment therefor. F5 · derivative.exercise_date: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 19:41 UTC | CEPHEID CPHD · Entity 181259 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 16,300 | $0.00 Strike: $45.59 | $0.00 |
DisclosureSEC source: 0001209191-16-148758 · doc4.xml · derivative · entry 5 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,300 shares Expires 2021-04-22 F3 · shares: Upon the Closing, 100% of these options were cancelled and converted into the right to receive an amount of cash equal to the number of shares outstanding under this option multiplied by $53 minus the option exercise price. F5 · derivative.exercise_date: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 19:41 UTC | CEPHEID CPHD · Entity 181259 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $38.13 | $0.00 |
DisclosureSEC source: 0001209191-16-148758 · doc4.xml · derivative · entry 4 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,800 shares Expires 2020-04-30 F3 · shares: Upon the Closing, 100% of these options were cancelled and converted into the right to receive an amount of cash equal to the number of shares outstanding under this option multiplied by $53 minus the option exercise price. F5 · derivative.exercise_date: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 19:41 UTC | CEPHEID CPHD · Entity 181259 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $35.72 | $0.00 |
DisclosureSEC source: 0001209191-16-148758 · doc4.xml · derivative · entry 3 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,800 shares Expires 2019-04-24 F3 · shares: Upon the Closing, 100% of these options were cancelled and converted into the right to receive an amount of cash equal to the number of shares outstanding under this option multiplied by $53 minus the option exercise price. F5 · derivative.exercise_date: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 19:41 UTC | CEPHEID CPHD · Entity 181259 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 18,750 | $0.00 Strike: $31.85 | $0.00 |
DisclosureSEC source: 0001209191-16-148758 · doc4.xml · derivative · entry 2 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,750 shares Expires 2018-04-26 F3 · shares: Upon the Closing, 100% of these options were cancelled and converted into the right to receive an amount of cash equal to the number of shares outstanding under this option multiplied by $53 minus the option exercise price. F4 · derivative.exercise_date: 1/3 of the shares subject to the grant vest and become exercisable on each anniversary of the grant date, subject to the continuing service of the Reporting Person on the vesting date. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 19:41 UTC | CEPHEID CPHD · Entity 181259 | Disposition to issuerCommon Stock | 14,677 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-148758 · doc4.xml · nonDerivative · entry 1 STEELE GLENN JR MD PHD · CIK 0001269131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: This number includes RSUs previously reported on Table I that at closing, were accelerated and converted into the right to receive $53 per share, without interest. F2 · price: On September 2, 2016, the Issuer entered into an Agreement and Plan of Merger ("Merger Agreement") with Danaher Corporation, a Delaware corporation (the "Acquirer"), and Copper Merger Sub, Inc., a California corporation and a wholly-owned subsidiary of the Acquirer. Upon the closing of the transactions contemplated by the Merger Agreement on November 4, 2016 (the "Closing"), each of the Reporting Person's shares of the Issuer's Common Stock was cancelled and converted into the right to receive $53.00, without interest (the "Merger Consideration"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.